Cointime

NovoCure

company

About

An Oncology Company Pioneering a Novel Therapy for Solid Tumors

  • 501 - 1000

Highlights

Total Funding Amount
$150M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$150M
Industries
Health Care,Medical Device
Founded date
Jan 1, 2000
Number Of Employee
501 - 1000
Operating Status
Active

Novocure™ is dedicated to the development of tumor treating fields therapy (NovoTTF™ Therapy), a new weapon for patients and physicians in the battle against cancer. NovoTTF Therapy is a novel anti-mitotic treatment that has been shown to slow or reverse tumor progression by inducing cell death in certain solid tumors. The company pioneered the concept that the electric properties of cells can be used as an effective target for an anti-neoplastic therapy.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$150M
NovoCure has raised a total of $150M in funding over 2 rounds. Their latest funding was raised on Nov 9, 2020 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 9, 2020 Post-IPO Debt $150M 1 JP Morgan Chase — Detail
Sep 28, 2009 Series Unknown — 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
NovoCure is funded by 2 investors. JP Morgan Chase and Pfizer are the most recent investors.
Investor Name Lead Investor Funding Round
JP Morgan Chase Yes Post-IPO Debt
Pfizer — Series Unknown
Cointime
İçerikler
Şirket.